SCI Cancer Clinical Trials Office Blog

News & Updates from the SCI-CCTO
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
  • Cancer Clinical Trials Office
  • Stanford Cancer Institute

Rule on Pathology Re-Read – Reminder

June 27, 2019 - SCI Communications

Source documentation is key in our business. So is precision. Confirming key results at Stanford Hospital and Clinics is part of our due diligence. All diseases diagnosed based off histological sections, morphological assessment of fine needle aspirates, bone marrow aspirates, or peripheral blood must have such diagnoses confirmed by a Medical Staff member with Pathology privileges at Stanford.

Therapy for clinical trials cannot be initiated prior that step. The exception – requiring detailed documentation by study principal investigator – is mandated urgent therapy.  If the pathology specimens cannot be obtained because they have been destroyed, no longer exist, or have been irrevocably lost or cannot be obtained through reasonable efforts, this should be documented in the medical record.

This recommendation (and exceptions) are part of the Rules and Regulations of medical staff bylaws available at Stanford governing documents homepage.

Blog Submissions

If you have an announcement for the blog, please contact SCI Communications.

Reminder: Please have your blog post submitted to us by noon on Wednesday in order to have your post featured in the weekly email digest on Friday morning.

Archives

Categories

  • Announcements
  • Clinical Trials
  • Coordinator Corner
  • Educational Training
  • Events
  • Intake Process
  • IRB Updates
  • OnCore
  • Quality Corner
  • Regulatory Updates
  • Remote Monitoring
  • SCI Messages
  • Scientific Review Committee (SRC)
  • SOP/Guideline Updates
  • Staff Updates
  • Uncategorized
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube